1.53
-0.03 (-1.92%)
-0.03 (-1.92%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Caladrius Biosciences Inc | CLBS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.03 | -1.92% | 1.53 | 18:16:24 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.56 | 1.50 | 1.59 | 1.57 | 1.56 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 1.50 | 1.57 | 0.07 | 1 | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 745 | 195,588 | $ 1.55 | $ 302,199 | 270,625 | 1.05 - 3.48 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:08:38 | formt | 2,000 | $ 1.53 | USD |
Caladrius Biosciences Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 29.68M | 19.40M | 17.87M | $ - | $ - | -1.88 | -2.40 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Caladrius Biosciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CLBS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.59 | 1.6402 | 1.48 | 1.58 | 237,155 | -0.06 | -3.77% |
| 1 Month | 1.47 | 1.65 | 1.37 | 1.54 | 214,422 | 0.06 | 4.08% |
| 3 Months | 1.68 | 1.75 | 1.25 | 1.53 | 208,229 | -0.15 | -8.93% |
| 6 Months | 2.7109 | 2.98 | 1.25 | 2.03 | 416,429 | -1.18 | -43.56% |
| 1 Year | 3.37 | 3.48 | 1.05 | 2.07 | 364,655 | -1.84 | -54.6% |
| 3 Years | 4.17 | 11.65 | 1.05 | 3.19 | 172,562 | -2.64 | -63.31% |
| 5 Years | 6.40 | 13.30 | 1.05 | 3.81 | 137,903 | -4.87 | -76.09% |
Caladrius Biosciences Description
| Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company developing cellular therapies designed to reverse, not manage, disease. The company's product candidates include: CLBS119, for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, clinical trial to be initiated in 3Q2020 (USA); CLBS12, recipient of a SAKIGAKE (Japan) and ATMP (Europe) designations, eligible for early conditional approval for the treatment of critical limb ischemia based on an ongoing clinical trial (Japan); CLBS16, subject of the completed proof-of-concept ESCaPE-CMD clinical and planned Phase 2B (U.S.A.); and CLBS14, a Phase 3 ready clinical program in no option refractory disabling angina and recipient of a RMAT designation (USA). |
